Osteoarthritis has been reported to affect 40 million Americans, involving more than 13 percent of the population. Eighty percent of those over the age of 50 are affected to some degree, and show radiographic evidence of osteoarthritic changes.1 A contributing cause of osteoarthritis is now thought to include the age-related decline in the body's synthesis of glucosamine, which appears to become pronounced by 45 to 50 years of age.2 Glucosamine sulfate is normally synthesized by chondrocytes and serves as the precursor to the production of N-acetyl-galactosamine sulfate, an essential component of chondroitin sulfate.
In the body, glucosamine is synthesized by the conversion of fructose-6 phosphate to glucosamine-6 phosphate by the enzyme, fructose-6 phosphate amide transferase, in the hexosamine biosynthetic pathway.3 As we age, it appears that the fructose-6 phosphate amide transferase enzyme concentrations decline or this enzyme becomes less active, resulting in the noted reduction in glucosamine synthesis seen with aging.2 Since the early 1980s, researchers have conducted a large number of clinical and experimental investigations to determine if oral glucosamine sulfate supplementation can compensate for the age-related decline in glucosamine synthesis, and thereby block the progression of osteoarthritis or reverse or repair any existing joint cartilage damage.4,5 In the past 20 years glucosamine sulfate has been the subject of more than 300 scientific investigations and over 20 double-blind clinical studies.2 In a recent meta-analysis addressing the efficacy of glucosamine sulfate for the treatment of osteoarthritis, researchers indicated that glucosamine supplementation was shown to be highly effective in the treatment of osteoarthritis in all 13 double-blind clinical trials that met the inclusion criteria.6
Absorption and Metabolism of Oral Glucosamine Sulfate
Glucosamine is a small and simple molecule that is readily absorbed from the gastrointestinal tract. Studies demonstrate that 90-98 percent of glucosamine sulfate is absorbed intact from the intestinal tract. By contrast, less than 13 percent of chondroitin sulfate is absorbed from the intestinal tract, making it significantly less effective than glucosamine sulfate as an intervention in the prevention and management of osteoarthritis.7-11 Once absorbed from the gut, glucosamine circulates through the bloodstream, where it can be taken up by cartilage cells (chondrocytes) and used to synthesize N-acetyl-galactosamine sulfate in the production of cartilage ground substance (glycosaminoglycans).3,12 The ground substance in joint cartilage fills in the gaps between the collagen fibers, which run parallel to each other within the cartilage. As an analogy, the collagen fibers are like the bricks of the cartilage structure, and the glycosaminoglycans are like the mortar between the bricks. Not only does glucosamine sulfate supplementation stimulate the synthesis of glycosaminoglycans, but it stimulates the synthesis of collagen by chondrocytes.13 As well, glucosamine sulfate is required for the synthesis of hyaluronic acid by the synovial membrane of the joint. Hyaluronic acid increases the viscosity of the synovial fluid and serves to reduce the wear-and-tear stress on the articular cartilage and related joint structures. Thus, glucosamine may be helpful in preventing, reversing or stabilizing the osteoarthritic process by stimulating the synthesis of glycosaminoglycans, collagen and hyaluronic acid.13,14
Essentially all of the research on glucosamine has employed the use of glucosamine sulfate, the only treatment approved for osteoarthritis in more than 70 countries around the world, used by millions of people for this purpose for more than 20 years.2 Glucosamine sulfate also delivers the mineral sulfur (hence the name glucosamine sulfate) to the joint cartilage. It has been recognized for many years that sulfur is a vital nutrient for the maintenance of joint cartilage. Sulfur is required to stabilize the connective tissue matrix of cartilage, tendons, and ligaments.15-19 As such, the use of glucosamine sulfate provides the joint structures with the mineral sulfur and glucosamine. This form of glucosamine offers a double benefit in the management of osteoarthritis cases.
Other forms of glucosamine are present in the commercial marketplace, such as N-acetyl-glucosamine and glucosamine hydrochloride. There is presently insufficient evidence to support their use and neither one of these forms provides the addition of the mineral sulfur, which has shown to be of value in osteoarthritis cases.2
Clinical Studies with Glucosamine Sulfate
Glucosamine sulfate has been the subject of more than 300 scientific investigations and over 20 double-blind clinical studies.2 In a recent meta-analysis of glucosamine clinical trials in the treatment of osteoarthritis, McAlindon and colleagues indicated that all 13 studies that met the inclusion criteria for double-blind, placebo-controlled trials of greater than four weeks' duration; using global pain score or the Lequesne index joint as the primary outcome measure and considered the trial positive if improvement in the treatment group was equal to or greater than 25 percent compared with the placebo group), were classified as positive, demonstrating that glucosamine supplementation is highly effective in the treatment of osteoarthritis. This meta-analysis revealed that glucosamine supplementation reduced the symptoms and signs of osteoarthritis by 40.2 percent on average, compared with the placebo.6
Glucosamine sulfate supplementation has also been investigated in head-to-head studies against nonsteroidal anti-inflammatory drugs (NSAIDs) in the treatment of osteoarthritis. In a number of these trials, glucosamine supplementation was shown to produce better results than ibuprofen and other NSAIDs in relieving the pain and inflammation of osteoarthritis. Unlike many NSAIDs, glucosamine has not been shown to produce any of the adverse side-effects that are frequently encountered with the use of NSAIDs (gastritis; peptic ulcer; GI bleeding and erosion of the intestinal lining; liver and kidney toxicity; and tinnitus).20-24
In a recent therapeutic investigation involving 178 Chinese patients suffering from osteoarthritis of the knee, the group given a daily dose of 1500mg of glucosamine sulfate demonstrated better results than did the group given ibuprofen at 1200mg per day (NSAID) with respect to reduction in symptoms of osteoarthritis. In this study, glucosamine sulfate was shown to be better tolerated than ibuprofen. Sixteen percent of the ibuprofen group dropped out due to adverse side-effects from the drug. A six-percent dropout rate occurred in the glucosamine group. The authors of the study concluded that glucosamine sulfate was a selective intervention for osteoarthritis, as effective on the symptoms of the disease as NSAIDs but significantly better tolerated. As such, glucosamine sulfate seems particularly indicated in the long-term treatment needed in osteoarthritis.25
In North America, the medical profession until recently took a more guarded view of glucosamine research, which has largely been performed in Europe and Asia. Concerns over research methodology and the validity of clinical findings have been raised, but it has been widely accepted that glucosamine is highly bioavailable (26 percent bioavailability after first pass through the liver to enter the bloodstream), and thus has the potential to slow or reverse osteoarthritic processes.26
These reports laid the foundation for the groundbreaking study published by Reginster, et al., in 1999 and 2001, published in Arthritis and Rheumatology (1999;42, supplement) and Lancet (2001;357). The three-year randomized study by Dr. Reginster was a large analysis that was placebo-controlled, double-blind, and prospective in nature. It involved 212 patients with knee osteoarthritis. Weightbearing and anteroposterior radiographs of each knee were obtained at one and three years, and joint space width was also measured. Symptom and functional status were scored every four months using the Western Ontario and McMaster University Osteoarthritis index (WOMAC). The two groups had comparable baseline status, but after three years there was no further joint space narrowing in the glucosamine group. The placebo group had further joint space narrowing and objective evidence of disease progression. Subject symptoms worsened in the placebo group, but the group taking glucosamine realized a marked reduction in symptoms of osteoarthritis over the three-year period. The authors concluded that glucosamine sulfate supplementation significantly reduced progression of knee osteoarthritis. Patients in the glucosamine group did not experience any untoward side-effects.27,28
"It is time for (medical doctors) to accommodate the possibility that many nutritional products may have valuable therapeutic effects and to regain the credibility of the public at large,"41 states the Lancet editorial.
Other Clinical Uses of Glucosamine
The clinical use of glucosamine supplementation may extend beyond the treatment of osteoarthritis. Glucosamine sulfate is also required for the synthesis of other glycosaminoglycans that are integral components of the basement membrane below the skin, intestinal tract lining and blood vessels. As reviewed by McCarty, glucosamine supplementation can be used to enhance wound healing (e.g., postsurgical) by stimulating the synthesis of hyaluronic acid. Experimental studies and human anecdotal evidence support this application.29 Glucosamine sulfate has also been used in a clinical trial involving 50 patients with temperomandibular disorders stemming from internal derangement and a diagnosis of osteoarthritis. These patients experienced decreased joint noises, pain and swelling after the administration of therapeutic doses of glucosamine and chondroitin sulfate.30 Experts in this area conclude, however, that adding chondroitin to glucosamine administration has not been shown to further improve the benefits available from glucosamine alone. At this time, the addition of chondroitin sulfate is seen to impose additional cost with no added benefit.13
There is also evidence to suggest that glucosamine sulfate supplementation may be beneficial as part of a nutritional regime to aid in the management of inflammatory bowel diseases. Experimental studies and human anecdotal evidence suggests that this may be the case. It is proposed that glucosamine supplementation can strengthen the basement membrane of gut blood vessels helping to prevent leakage of blood into the intestinal lumen, which may otherwise trigger an inflammatory immune reaction. Further, glucosamine has been shown to have a healing effect on the mucosal lining of the G I tract itself. Anecdotal evidence supports the trial of glucosamine in both Crohn's disease and ulcerative colitis.31,38
As well, the decline in glucosamine sulfate synthesis with age may imply that a prudent anti-aging strategy may be to use a low-to-moderate dose of glucosamine sulfate (500mg per day) as a prevention strategy beginning at 45-50 years of age. This intervention may help to prevent or minimize the age-related biochemical changes that are linked to the development of osteoarthritis, helping to preserve quality of life to a significant degree. This practice may also serve to reduce the chances of capillary fragility that is associated with risk of stroke and vein disorders, also seen with increasing frequency with advancing age.
Finally, it should be noted that the heparan sulfate (a glycosaminoglycan made from glucosamine sulfate) content of ground substance between body cells has also been shown in animal experiments to reduce the ability of cancer cells to metastasize. The metastatic capacity of cancer cells tends to correlate with their ability to produce heparanase enzyme. Heparanase enzyme eats through the heparan sulfate ground substance (mortar) between cells, through the secretion of heparanase enzyme. Once again, glucosamine sulfate is required for the optimum synthesis of heparan sulfate, thickening the mortar between cells and making it more difficult for heparanase enzyme to break it down. With the realization that heparan sulfate production may decline as we age due to reduced glucosamine sulfate synthesis, the prophylactic administration of glucosamine may also be of value in these facets of disease prevention.32-37
Side-Effects, Toxicity and Contra-Indications to the Use of Glucosamine
Reported short-term adverse side-effects from the use of glucosamine are generally mild and infrequent. These include mild gastrointestinal upset, drowsiness, skin reactions, and headache.26 Glucosamine sulfate has been shown to be non-toxic at prescribed doses.14 Patients allergic or sensitive to sulfa drugs or sulfate-containing food additives can safely take glucosamine sulfate. The word "sulfate" in this instance indicates the presence of the mineral sulfur, not the sulfa compounds used in sulfa drugs and sulfate-containing food additives.
All cells of the body contain the mineral sulfur and thus, it is not possible to be allergic to this mineral. However, glucosamine sulfate is manufactured from the chitin exoskeleton of shellfish, such as lobster crab and shrimp. Therefore, it is conceivable that a person with a severe allergy to shellfish may be sensitive to the use of glucosamine, although the pharmaceutical grade of glucosamine is generally devoid of shellfish contaminants. Nevertheless, caution should be exercised in these cases.2,14
Some preliminary animal experiments and human trials on healthy people reveals that glucosamine supplementation may increase insulin resistance in some by down-regulating the synthesis of insulin receptors by the nuclear DNA.39 In large clinical trials this has not surfaced as a concern, and no indication of pronounced glucose intolerance has been demonstrated in the many well-documented glucosamine studies, including one in Lancet and the glucosamine meta-analysis appearing in JAMA.22,40 It is advisable for diabetic and pre-diabetic patients to have their blood glucose monitored during the first few weeks of glucosamine sulfate supplementation. These conditions are not an absolute contra-indication to the use of glucosamine.
In regards to the treatment of osteoarthritis, the usual daily dosage of glucosamine sulfate is 1500mg, which can be taken all at one time28 or in divided doses of 500mg per dose.2,14 Individuals taking diuretic drugs may require an additional 500mg per day to compensate for the increased excretion rate. Individuals weighing more than 200 pounds may also be advised to up their dosage to 2000mg per day.2
In many European countries, glucosamine is available only by prescription from a medical practitioner. In North America, glucosamine is classified as a natural health product and is readily available as an over-the-counter product. As such, glucosamine products are held to much lower standards in purity and potency than prescription medications. A recent independent study revealed that up to one third of the glucosamine products tested did not contain the amount of glucosamine stated on the label.42 For this reason, it is imperative that health practitioners recommend only those glucosamine products whereby the manufacturer can issue a certificate of analysis or a third party true-to-label claim document that verifies the purity and potency of the product. This should be a standing policy for practitioners in recommending all herbal or accessory nutrient supplements (e.g., glucosamine, CoQ-10, MSM).
The current research status of glucosamine sulfate supports its use as a safe and effective biochemical intervention in the treatment of osteoarthritis. It should complement other natural therapies (e.g., manipulation, mobilization, soft tissue therapies, acupuncture electro-modalities), exercise and other evidence-based dietary and supplementation measures as part of the holistic management of osteoarthritic cases. There is also encouraging evidence to support its use as a natural agent that may be useful in the management of inflammatory bowel diseases, and possibly as an intervention to prevent age-related biochemical changes associated with the development of osteoarthritis and other degenerative conditions.
- Bland JH, Cooper SM. Osteoarthritis: A review of the cell biology involved and evidence for reversibility. Management rationally related to known genesis and pathophysiology. Sem Arthr Rheum 198414;106-33.
- Murray MT. Glucosamine sulfate: nature's arthritis cure. Excerpt from The Chiropractic Journal March 1998.
- Basic Medical Biochemistry: A Clinical Approach. Williams & Wilkins1996:452-453.
- Glucosamine sulfate. Altern Med Rev 1999 Jun;4(3):193-5 (ISSN: 1089-5159).
- Vidal Y, Plana RR, et al. Articular cartilage pharmacology. In vitro studies on glucosamine and nonsteroidal anti-inflammatory drugs. Pharmacol Res Comm 1978;10:557-569.
- Deal CL, Moskowitz RW. Nutraceuticals as therapeutic agents in osteoarthritis. The role of glucosamine, chondroitin sulfate, and collagen hydrolysate. Rheum Dis Clin North Am May 2000; 25(2):79-95 (ISSN: 0889-857X)
- Setnikar I, et al: Pharmacokinetics of glucosamine in the dog and man. Arzneim Forsch 1993;43: (10):1109-13.
- Setnikar I, et al: Pharmacokinetics of glucosamine in the dog and man. Arzneim Forsch 1986;36 (4) 729-35.
- Baici A, et al. Analysis of glycosaminoglycans in human sera after oral administration of chondroitin sulfate. Rheumatol Int 1992;12:81-8.
- Conte A, et al. Biochemical and pharmacokinetic aspects of oral treatment with chondroitin sulfate. Arzneim Forsch 1995;45:918-25.
- Baici A, Wagenhauser FJ. Bioavailability of oral chondroitin sulfate. Rheumatology Int. 1993 13:41-43.
- Peperno M, Reboul P, Le Graverand H, Peschard JJ, Annefeld M, Richard M, Vignon E. Glucosamine sulfate modulates dysregulated activities of human osteoarthritic chondrocytes in vitro. Osteoarthritis Cartilage May 2000;8(3):207-12 (ISSN: 1063-4584)
- Kelly GS. The role of glucosamine sulfate and chondroitin sulfates in the treatment of degenerative joint disease. Altern Med Rev Feb 1998;3(1):27-29 (ISSN: 1089-5159).
- Gottlieb MS. Conservative management of spinal osteoarthritis with glucosamine sulfate and chiropractic treatment. Journal of Manipulative and Physiological Therapeutics July/August 1997; Vol. 20(6).
- Sullivan MS, Hess WC. Cysteine content of fingernails in arthritis. J Bone Joint Surg 1935;16: 185-8.
- Senturia BD. Results of treatment of chronic arthritis and rheumatoid conditions with colloidal sulphur. J Bone Joint Surg 1934;16:119-25.
- Lawrence RM. Methylsulfonylmethane (MSM): A double-blind study of its use in degenerative arthritis. Int J Anti-Aging Med 1998;1:1:50
- Challem J. Sulfur power. Natural Way For Better Health (magazine) 1999(02/28):34-35
- Methylsulfonylmethane (MSM). Herbal Advisor. www.herbaladvisor.com, 2001 Samtech Research.
- Noack W, et al. Glucosamine sulfate in osteoarthritis of the knee. Osteoarthritis Cartilage 1994;2;51-9.
- Vaz AL. Double-blind clinical evaluation of the relative efficacy of ibuprofen and glucosamine sulfate in the management of osteoarthrosis of the knee in outpatients. Curr Med Res Opn 8;145-9, 1982.
- Muller-Fassbender H, et al. Glucosamine sulfate compared to ibuprofen in osteoarthritis of the knee. Osteoarthritis Cartilage 1994;2:61-9.
- Rovati LC, et al. A large randomized placebo-controlled, double-blind study of glucosamine sulfate vs. piroxicam and vs. their association on the kinetics of the symptomatic effect in knee osteoarthritis. Osteoarthritis Cartilage 1994;2 (suppl 1):56.
- Tapadinhas MJ, et al. Oral glucosamine sulfate in the management of arthrosis: report on a multi-centre open investigation in Portugal. Pharmatherapeutica 1982;3:157-68.
- Qiu GX, Gao SN, Giacovelli G, Rovati, L Setnikar I. Efficacy and safety of glucosamine sulfate versus ibuprofen in patient with knee osteoarthritis. Arzneimittelforschung May 1998;48(5):469-74 (ISSN: 0004-4172).
- Barclay TS, Tsourounis C, McCarty GM. Glucosamine. Ann Pharmacother May 1998;32(5):574-9 (ISSN: 1060-0280).
- Reginster YJ, Deroisy R, Paul I, et al. Glucosamine sulfate significantly reduces progression of knee OA over three years: a large randomized, placebo-controlled, double-blind prospective trial. Arthritis Rheum. 1999;42 (suppl).
- Reginster JY, Deroisy R, Rovati LC, Lee RL, Lejeune E, Bruyere O, Giacovelli G, Henrotin Y, Dacre JE, Gossett C. Long-term effects of glucosamine sulphate on osteoarthritis progression: a randomized, placebo-controlled clinical trial. Lancet 2001 Jan. 27;357(9252):251-6 (ISSN: 0140-6736).
- McCarty MF. Glucosamine for wound healing. Medical Hypotheses 1996;47;273-275.
- Shankland WE. The effects of glucosamine and chondroitin sulfate on osteoarthritis of the TMJ: a preliminary report of 50 patients. Cranio Oct. 1998;16(4):230-5 (ISSN: 0886-9634).
- McCarty MF. Vascular heparan sulfates may limit the ability of leukocytes to penetrate the endothelial barrier - implications for use of glucosamine in inflammatory disorders. Med Hypotheses 1998;51(1):11-15.
- Vlodavsky I, Fuks Z, Bar-Ner M, et al. Lymphoma-cell-mediated degradation of sulfated proteoglycans in the subendothelial extracellular matrix: Relationship to tumor cell metastasis. Cancer Res 1983;43:2704-2711.
- Nakajima M, Irimura T, Di Ferrante D, et al. Heparan sulfate degradation: Relation to tumor invasion and metastatic properties of mouse B16 melanoma sublines. Science 1983;220:611-612.
- Ricoveri W, Cappelletti R. Heparan sulfate endoglycosidase and metastatic potential in murine fibrosarcoma and melanoma. Cancer Res 1986;45:3855-3861.
- Nakajima M, Irimura T, Nicolson GL. Heparanase and tumor metastasis. J Cell Biochem 1988;36: 157-167.
- Vlodavsky I, Eldor A, Bar-Ner M, et al. Heparan sulfate degradation in tumor cell invasion and angiogenesis. Adv Exp Med Biol 1988;233:201-210.
- Vlodavsky I, Korner G, Ishai-Michaeli R, et al. Extracellular-matrix-resident growth factors and enzymes: Possible involvement in tumor metastasis and angiogenesis. Cancer Metastasis Rev 1990;9:203-226.
- Russell AL. Glucosamine in osteoarthritis and gastrointestinal disorders: an example of the need for a paradigm shift. Med Hypotheses Oct 1998;51(4):347-9 (ISSN: 0306-9877).
- Monauni T, Zenti MG, Cretti A, et al. Effects of glucosamine infusion on insulin secretion and insulin action in humans. Diabetes Jun 2000;49(6):926-35 (ISSN: 0012-1797).
- McAlindon TE, La Valley MP, Gulin JP, Felson DT. Glucosamine and chondroitin for treatment of osteoarthritis: a systematic quality assessment and meta-analysis. JAMA Mar. 2000;15;283(11): 1469-75 (ISSN: 0098-7484).
- McAlindon T. Glucosamine for osteoarthritis: dawn of a new era? Lancet 2001;357,9252:247-248.
- Nutrition News Focus, February 13, 2001.
Click here for more information about James P. Meschino, DC, MS.